Harbin Gloria Pharmaceuticals Strategic Asset Allocation Index
Harbin Gloria Pharmaceuticals strategic asset allocation index. Harbin Gloria Pharmaceuticals (002437) has a Strategic Asset Allocation Index of 58.1% as of September 2023. Strategic assets (PP&E of CN¥1.08 Billion plus long-term investments of CN¥-) total CN¥1.08 Billion, measured against net assets of CN¥1.86 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Harbin Gloria Pharmaceuticals's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Harbin Gloria Pharmaceuticals (2010–2021)
Strategic asset allocation index of Harbin Gloria Pharmaceuticals from 2010 to 2021. This chart shows how Harbin Gloria Pharmaceuticals's Strategic Asset Allocation Index has evolved across 12 annual periods from 2010 to 2021. As of September 2023, the index stands at 58.1%, representing strategic assets of CN¥1.08 Billion against net assets of CN¥1.86 Billion CNY. Check Harbin Gloria Pharmaceuticals (002437) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Harbin Gloria Pharmaceuticals Strategic Asset Allocation Index by Year (2010–2021)
Harbin Gloria Pharmaceuticals strategic asset allocation index by year from 2010 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Harbin Gloria Pharmaceuticals from 2010 to 2021, covering 12 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Harbin Gloria Pharmaceuticals stock valuation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 62.4% | CN¥1.24 Billion | CN¥1.24 Billion | CN¥- | CN¥1.98 Billion | ▼ -6.9 pp |
| 2020 | 69.3% | CN¥1.34 Billion | CN¥1.34 Billion | CN¥- | CN¥1.93 Billion | ▼ -25.2 pp |
| 2019 | 94.5% | CN¥1.50 Billion | CN¥1.50 Billion | CN¥- | CN¥1.59 Billion | ▲ +37.9 pp |
| 2018 | 56.6% | CN¥2.49 Billion | CN¥1.72 Billion | CN¥766.54 Million | CN¥4.39 Billion | ▲ +2.6 pp |
| 2017 | 54.0% | CN¥2.30 Billion | CN¥1.78 Billion | CN¥517.83 Million | CN¥4.25 Billion | ▼ -2.7 pp |
| 2016 | 56.7% | CN¥2.30 Billion | CN¥1.81 Billion | CN¥480.37 Million | CN¥4.05 Billion | ▲ +4.9 pp |
| 2015 | 51.8% | CN¥1.80 Billion | CN¥1.64 Billion | CN¥154.68 Million | CN¥3.47 Billion | ▲ +25.0 pp |
| 2014 | 26.8% | CN¥831.40 Million | CN¥831.40 Million | CN¥- | CN¥3.10 Billion | ▼ -0.2 pp |
| 2013 | 27.0% | CN¥668.68 Million | CN¥668.68 Million | CN¥- | CN¥2.48 Billion | ▲ +3.2 pp |
| 2012 | 23.8% | CN¥560.95 Million | CN¥560.95 Million | CN¥- | CN¥2.36 Billion | ▲ +4.8 pp |
| 2011 | 18.9% | CN¥416.25 Million | CN¥416.25 Million | CN¥- | CN¥2.20 Billion | ▲ +6.4 pp |
| 2010 | 12.6% | CN¥266.93 Million | CN¥266.93 Million | CN¥- | CN¥2.12 Billion | — |